Business
Pathos AI commits to USD 2.2b deal for first-in-class TROP2/HER3 bispecific ADC from Alphamab
Pathos AI has licensed exclusive ex-Greater China rights to JSKN016, a bispecific antibody-drug conjugate (ADC) simultaneously targeting TROP2 and HER3,...
BlossomHill unveils USD 125m IPO terms as lead EGFR program advances
San Diego-based BlossomHill Therapeutics, Inc. (Nasdaq: BLSM), a clinical-stage oncology company whose lead program targets a form of EGFR-mutant lung...
AstraZeneca licenses preclinical ERα PROTAC AZD4241 to Pathos AI
Pathos AI, a privately held AI-native oncology company, has entered a collaboration and co-exclusive licensing agreement with AstraZeneca (LSE/Nasdaq: AZN)...
Roche partners with Evexta Bio to test dual-node inhibitor against resistant breast cancer
France-based Evexta Bio S.A. and Roche announced a clinical trial collaboration and supply agreement to evaluate rupitasertib in combination with...
Ceruvia funds Phase I/II trial of non-hallucinogenic LSD analog for cluster headache
Greenwich, Connecticut-based Ceruvia Lifesciences announced a USD 8 million founder-backed investment to fully fund an integrated Phase I/II clinical study...
Obsidian completes Galera reverse merger and USD 350m PIPE raise
Cambridge, Massachusetts-based Obsidian Therapeutics (Nasdaq: OBX) completed its reverse merger with Galera Therapeutics on August 3, 2026, simultaneously...
CellOrigin advances in vivo mRNA CAR-T for HCC with Walvax partnership
China-based CellOrigin Biotech (Hangzhou) Co., Ltd. has entered a co-development agreement with Walvax Biotechnology Co., Ltd. (Shenzhen: 300142) to jointly...
Moleculin raises USD 9.3m to fund Annamycin's pivotal AML trial through interim readout
Houston-based Moleculin Biotech, Inc. (Nasdaq: MBRX) announced the pricing of a USD 9.3 million best-efforts public offering on July 31, 2026, with proceeds...
Nippon Shinyaku exercises USD 30 million option for AB2 Bio's rare disease biologic
Japan-based Nippon Shinyaku Co., Ltd. (TSE: 4516) has exercised its option to acquire exclusive US commercialization rights to tadekinig alfa,...
Supernus, Indivior agree all-stock merger to create diversified CNS biopharma
Rockville, Maryland-based Supernus Pharmaceuticals (Nasdaq: SUPN) and Richmond, Virginia-based Indivior Pharmaceuticals (Nasdaq: INDV) have agreed to merge...
Curium to acquire Lantheus for USD 8b to build global radiopharmaceutical powerhouse
Curium, the Boston-headquartered global radiopharmaceutical company controlled by private equity firm CapVest Partners LLP, has agreed to acquire Lantheus...
China's Ractigen raises USD 31m to expand saRNA pipeline
China-based Ractigen Therapeutics has closed a financing round exceeding USD 31 million (CNY 200 million) to advance its clinical-stage small activating RNA...
Nabsys expands electronic genome mapping into AML and MDS through Indiana University partnership
Providence, Rhode Island-based Nabsys 2.0, LLC announced a multi-year research collaboration with the Indiana University School of Medicine to evaluate its...
Ratio Therapeutics raises USD 70m Series C with Eli Lilly as new strategic investor
Boston-based Ratio Therapeutics, Inc., a clinical-stage radiopharmaceutical company, has closed a USD 70 million Series C financing round, bringing total...
Annexon secures USD 200m credit facility as late-stage programs approach market approvals
Brisbane, California-based Annexon, Inc. (Nasdaq: ANNX) announced a senior secured credit facility of up to USD 200 million from Oxford Finance LLC,...
The AllSci Brief
Free, systematic R&D and deal news. Daily.